In the News April 2013 JDRF is the only global organization with a strategic plan to deliver a continuous flow of life-changing therapies and, ultimately, a cure for T1D. Past JDRF investments have yielded significant advances and taught us that progress towards our goals will be made incrementally over time. ...
Glucose Meter Recall
LifeScan Announces Voluntary Recall of All OneTouch® Verio®IQ Blood Glucose Meters At extremely high blood glucose levels (1024 mg/dL and above), the OneTouch® Verio®IQ Meter will not provide a warning and will shut off Milpitas, CA – March 25, 2013 – LifeScan, Inc. is initiating a voluntary recall and...
Recycling for JDRF
The company does printer cartridge and battery recycling and sends the proceeds to JDRF! Conover Office Products Mark Conover-Owner120 Point West Blvd.St. Charles, MO 63301 Mark@conoverofficeproducts.com 636.720.1354 Read more »
Millstadt Optimist Club Fundraising
At a recent Millstadt Optimist club meeting they announced the final total raised for JDRF at their annual Fall Chilli Cookoff, $22,776.80. And they announced we would again be their charity of choice for 2013! This group spends many many hours putting together an event that brings in the public...
JDRF Comments on Economic Impact of Diabetes
New York, NY, March 6, 2013—Health economists funded by the American Diabetes Association released an update today of their analysis of the costs of diabetes in the United States, noting an increase in cost of 41 percent, from $174 billion in 2007 to $245 billion in 2012. The analysis points...
Cool Research News – Fall 2012
Whether you are newly diagnosed or have been living with type 1 diabetes (T1D) for a long time, JDRF is committed to improving the lives of all people affected by the disease. We aim to accelerate the progress of research to provide better treatments, prevention, and ultimately a cure for...
JDRF Named All-Star Charity
Forbes Picks 5 All-Star Charities: Top Rankings For Efficient Groups Some single-disease charities spend a lot of money soliciting contributions by mail. JDRF (it recently renamed itself from the Juvenile Diabetes Research Foundation to reflect the varied ages of Type 1 diabetes patients) holds down costs by relying on a...
Dinner with Ryan Reed
Several weeks ago, Seth and I were fortunate enough to have dinner with up-and-coming Nascar driver Ryan Reed and his family while they were in San Diego for an event. We met them at Roy’s on the Bay Downtown, and ended up having a wonderful evening filled with fabulous conversation....
e-Cycle Continues its Charitable Mission with Mobile Buyback Campaign
e-Cycle, the well-known mobile buyback and recycling company, goes beyond offering innovative green business solutions and is dedicated to offering exceptional customer service and community support through charitable contributions and philanthropy. In keeping with its social commitment, it is working hard to raise funds to support the cause of type...
FDA Approval of Lucentis for the Treatment of Diabetic Macular Edema
On August 10, the drug Lucentis, licensed by Genentech, was approved by the U.S. Food and Drug Administration (FDA) for the treatment of diabetic macular edema (DME). Studies of Lucentis (ranibizumab injection)—funded by JDRF and the National Institutes of Health’s (NIH) Special Diabetes Program (SDP)—demonstrated the drug’s safety and effectiveness...
Research Funding
On August 3, JDRF, in collaboration with The Leona M. and Harry B. Helmsley Charitable Trust, announced the award of a $4.6 million grant to the laboratory of Camillo Ricordi, M.D., of the Diabetes Research Institute at the University of Miami. The three-year grant will fund research in the area...
Combination Therapy May Help in Islet Transplant Failure
JDRF-funded scientists provided new evidence that a two-drug combination can extend the function of pancreatic islet transplants that have begun to fail and restore insulin independence in some transplant recipients with type 1 diabetes (T1D). This research finding was presented at the American Diabetes Association’s 72nd Scientific Sessions in Philadelphia...
50-Year Medalist Study Shows Positive Results
The JDRF-supported Joslin 50-Year Medalist Study has shown that more than 40 percent of people who have had type 1 diabetes (T1D) for at least 50 years have no or mild diabetic retinopathy, or eye disease, suggesting that many of the Medalists are somehow protected from this common complication of...
Progress in Testing Artificial Pancreas Systems in Clinical and Real-World Settings
Two JDRF-funded pilot trials in human subjects represent significant advances in the development of a safe and effective artificial pancreas system for the treatment of type 1 diabetes (T1D). One study demonstrated, for the first time, the feasibility of a wearable artificial pancreas in a “real-world” setting. The second study...
Top Research Highlights, Summer 2012
Advancing Type 1 Diabetes Science Every day, JDRF leverages the expertise and innovation of distinguished researchers from across the globe to support better treatments, prevention, and ultimately a cure for type 1 diabetes (T1D). In this issue of Top Research Highlights, please read about news from the American Diabetes Association’s...
Researchers Formulate Stable Liquid Glucagon
The search for a stable liquid formulation of glucagon has occupied many diabetes researchers for years. While currently the biosynthetic hormone is manufactured in dry form to ensure stability and shelf life, the delivery of glucagon in conjunction with insulin in standard diabetes pumps—a long-sought development— would require a viable...
Final FDA Artificial Pancreas Guidance a Milestone for People with Type 1 Diabetes
The FDA’s final artificial pancreas guidance adopts JDRFs recommendations, providing a clear path toward improving lives by moving the transformative technology into the hands of millions with type 1 diabetes Contact: William Sorensen, 212-479-7558; wsorensen@jdrf.org New York, NY, November 13, 2012-JDRF today called the Food and Drug...
T1D in the Family
On Thursday, November 15th during News Channel 5 at Noon, Kay Quinn interviewed Linda & Rebecca Short about T1D in the Short Family. Rebecca Short was diagnosed with T1D at the age of 22 months. Now 12 years old, she and her family have lived with T1D for over 10...
The Folly of Defunding Diabetes Research
(reprinted from The Wall Street Journal) By WOODY JOHNSON While most people know me as owner of the New York Jets, my passion has long been in a different field: finding a cure for diabetes, one of America’s most devastating diseases. Researchers are on the verge of...
Medical Waste Program
Click here to learn more about Waste Management’s mail-order medical waste disposal, MedWaste Tracker. Put in referral code #177591 for a $10 discount. Read more »